As of May 27, 2025, Sigilon Therapeutics Inc (SGTX) reports a Gross Margin of 7775.20%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Comparing Sigilon Therapeutics Inc's Gross Margin to Peers
To better understand Sigilon Therapeutics Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Sigilon Therapeutics Inc (SGTX) | 7775.20% |
| IDEAYA Biosciences Inc (IDYA) | 7775.20% |
| Harpoon Therapeutics Inc (HARP) | 7775.20% |
| Chinook Therapeutics Inc (KDNY) | 7775.20% |
| Merus NV (MRUS) | 7775.20% |
| Oric Pharmaceuticals Inc (ORIC) | 7775.20% |
Compared to its competitors, Sigilon Therapeutics Inc's Gross Margin is higher than all peers, indicating superior product pricing power or cost efficiency in production.